1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
Real-time Euronext Paris  -  11:35 2022-07-05 am EDT
3.260 EUR   -0.61%
06/24NANOBIOTIX : Resultat AGM 2022 06 23 Vote Publication SAF-2
PU
06/07NANOBIOTIX : New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications - Form 6-K
PU
06/07NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
3.445(c) 3.365(c) 3.385(c) 3.28(c) 3.26(c) Last
102 431 126 884 65 093 31 397 69 057 Volume
-3.50% -2.32% +0.59% -3.10% -0.61% Change
More quotes
Estimated financial data (e)
Sales 2022 1,25 M 1,28 M 1,28 M
Net income 2022 -54,7 M -56,1 M -56,1 M
Net Debt 2022 17,1 M 17,6 M 17,6 M
P/E ratio 2022 -2,08x
Yield 2022 -
Sales 2023 1,36 M 1,39 M 1,39 M
Net income 2023 -103 M -105 M -105 M
Net Debt 2023 0,40 M 0,40 M 0,40 M
P/E ratio 2023 -2,05x
Yield 2023 -
Capitalization 114 M 116 M 116 M
EV / Sales 2022 105x
EV / Sales 2023 83,9x
Nbr of Employees 100
Free-Float 94,5%
More Financials
Company
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the... 
More about the company
Ratings of Nanobiotix
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NANOBIOTIX
06/24NANOBIOTIX : Resultat AGM 2022 06 23 Vote Publication SAF-2
PU
06/07NANOBIOTIX : New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting..
PU
06/07NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the Americ..
CI
06/06Nanobiotix's Radiotherapy-activated Therapy Shows Potential In Treatment Of Head, Neck,..
MT
06/05NANOBIOTIX : Inside Information / Other news releases
PU
06/05NANOBIOTIX : New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting..
BU
06/05Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the A..
CI
06/02NANOBIOTIX : Detailed text of resolutions
PU
06/02NANOBIOTIX : Annual Shareholders' General Meeting to Be Held on June 23, 2022 - Form 6-K
PU
06/02NANOBIOTIX Annual Shareholders' General Meeting to Be Held on June 23, 2022
BU
05/18CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd..
BU
05/18NANOBIOTIX Provides First Quarter Operational and Financial Update
BU
05/18NANOBIOTIX : 1st quarter results
CO
05/17NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
BU
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
More news
News in other languages on NANOBIOTIX
06/24NANOBIOTIX : Assemblée Générale, résultat du vote des résolutions
06/15NANOBIOTIX : Avis de convocation – BALO 8 juin 2022
06/07NANOBIOTIX : plus forte baisse du SRD à la clôture du mardi 7 juin 2022
06/07NANOBIOTIX annonce la communication de nouvelles données lors de la réunion annuelle de..
06/07NANOBIOTIX : A suivre aujourd'hui
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,26 €
Average target price 22,20 €
Spread / Average Target 581%
EPS Revisions
Managers and Directors
Laurent Lévy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Christophe Douat Member-Supervisory Board
Anne-Marie Graffin Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
NANOBIOTIX-55.13%119
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-7.58%19 151